<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<html lang="en">
<head><meta http-equiv="Content-Type" content="text/html; charset=">
<title>Town Hall Production Ticket
</title>
</head>

<body >
<h1>
<a name="_Toc508027836"></a><a name="_Toc508028065"></a><a name="_Toc508029544"></a><a name="_Toc510101371"></a><a name="_Toc510101425"></a><a name="_Toc510106494"></a><a name="_Toc512249899"></a><a name="Heading1"></a>Town Hall Production Ticket</h1>
<p><a name="_Toc510101372"></a><a name="_Toc510101426"></a><a name="_Toc510106495"></a>For registration pages and certificate pages</p>

<p>Sections highlighted in blue should be reviewed by the SD during Content Check THPT task</p>

<p>Sections highlighted in pink should be reviewed by the SD before Copyedit of the live event</p>

<p>Sections highlighted in dark yellow should be reviewed by the SD for the enduring activity</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Who?</strong></p>
</td>
<td><p><strong>When?</strong></p>
</td>
<td><p><strong>What?</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>R Sheridan</p>
</td>
<td><p>4 Sept 2018</p>
</td>
<td><p>Initiate ticket</p>
</td>
</tr>

<tr valign="top">
<td><p>W Guerra</p>
</td>
<td><p>10/2/2018</p>
</td>
<td><p>Complete THPT</p>
</td>
</tr>

<tr valign="top">
<td><p>R Sheridan</p>
</td>
<td><p>08 Oct 2018</p>
</td>
<td><p>Completeness check</p>
</td>
</tr>

<tr valign="top">
<td><p>K MacDougall</p>
</td>
<td><p>10/12/2018</p>
</td>
<td><p>Copyedit</p>
</td>
</tr>

<tr valign="top">
<td><p>W Guerra</p>
</td>
<td><p>10/21/18</p>
</td>
<td><p>Review CE and prep for CME</p>
</td>
</tr>

<tr valign="top">
<td><p>E Nyarko</p>
</td>
<td><p>10/24/18</p>
</td>
<td><p>Expedited OUS TH Enduring Content Review</p>
</td>
</tr>

<tr valign="top">
<td><p>W Guerra</p>
</td>
<td><p>10/24/18</p>
</td>
<td><p>Prep for production</p>
</td>
</tr>

<tr valign="top">
<td><p>R Sheridan</p>
</td>
<td><p>10/24/18</p>
</td>
<td><p>Create sync sheet/downloadable deck;  Add materials to drop folder</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<p></p>
<h1>
<a name="HandoffNotes"></a><a name="_Toc512249900"></a><a name="Heading40"></a>Handoff Notes and Reminders</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>To Scientific Directors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Copyeditors</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To Production/Studio &#953;</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>To CME Department</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<p></p>

<p>Contents</p>
<h1>
<a name="_Toc512249901"></a><a name="Heading86"></a>General Event Information</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Destination URL: </strong></p>

<p>(e.g., <a href="http://www.medscape.org/sites/townhall/public/gvhd">www.medscape.org/sites/townhall/public/gvhd</a>)</p>

<p>Note: this should <strong><em><u>not be</u></em></strong> the vanity URL</p>
</td>
<td><p>www.medscape.org/sites/townhall/public/smoking-cessation-Munich2018</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Live streaming event?</strong></p>
</td>
<td><p>Choose an item.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Activity Overview </strong></p>

<p><em>(event description &#8211; 150 words maximum)</em></p>
</td>
<td><p>During this interactive symposium, leading experts will review the available pharmacologic therapies for smoking cessation and also the alternative approaches that are used by patients who wish to stop smoking. The agenda will include a review of the supporting data for these methods, and faculty will explore the issues and controversies regarding the use of each approach in smoking cessation. </p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="_Toc512249902"></a><a name="Heading99"></a>Registration/Overview Info</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Title:</strong></p>
</td>
<td><p>The Big Debate: Pharmacologic vs Alternative Approaches in Smoking Cessation</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Subtitle:</strong></p>

<p><strong>*Title + subtitle = 100 characters max, incl spaces*</strong></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Teaser (140 characters max incl. spaces)</strong></p>
</td>
<td><p>Drs Aubin, Hajek, Toennesen, and Tonstad explore the issues regarding the available management approaches to smoking cessation.</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Faculty/Author(s) Byline(s)</strong></p>

<p>(Names and degrees only, separated by semicolons)</p>
</td>
<td><p>Henri-Jean Aubin, MD, PhD; Peter Hajek, PhD; Serena Tonstad, MD, PhD</p>
</td>
</tr>

</table>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Location/map info:</strong></p>

<p><strong>(City, State &#8211; Venue, Room)</strong></p>
</td>
<td><p>Ludwig-Maximilians-University, Psychiatric Clinic, Munich, Germany</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Date &amp; Time:</strong></p>
</td>
<td><p>September 7, 2018 at 12:30 to 13:30</p>
</td>
</tr>

</table>
<h1>
<a name="_Toc512249903"></a><a name="Heading117"></a>Speakers/Program Info/Faculty information/Disclosures</h1>
<p><strong>*Disclosures are not to be used for the registration page*</strong></p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Speakers</strong></p>

<p><em>Names, title, affiliations </em></p>

<p><em>Disclosures </em></p>

<p>(Disclosures not to be used for the registration page, only for the certificate and enduring page)</p>

<p><strong>eg:</strong></p>

<p>Moderator</p>

<p>Aldo P. Maggioni, MD</p>

<p>Director </p>

<p>Research Center of Italian Association of Hospital Cardiologists (ANMCO) </p>

<p>Firenze, Italy</p>

<p>Disclosure: Aldo P. Maggioni, MD, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for:...</p>

<p>Panelists</p>

<p>Clyde W. Yancy, MD, MSc</p>

<p>Magerstadt Professor of Medicine</p>

<p>Chief</p>

<p>Division of Cardiology </p>

<p>Northwestern University Feinberg School of Medicine</p>

<p>Chicago, Illinois, United States</p>

<p>Disclosure: Clyde W. Yancy, MD, MSc, has disclosed the following relevant financial relationships:</p>

<p>Served as an advisor or consultant for:...</p>
</td>
<td><p></p>

<p>Henri-Jean Aubin, MD, PhD</p>

<p>Professor</p>

<p>University Paris-Sud</p>

<p>Director of the Addiction Science Research Group in the INSERM 1018 Unit</p>

<p>Villejuif, France</p>

<p>Disclosure: Henri-Jean Aubin, MD, PhD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: D&amp;A Pharma; Ethypharm; Lundbeck, Inc.; Pfizer Inc. </p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: Lundbeck, Inc.; Merck &amp; Co., Inc.; Novartis Pharmaceuticals Corporation; Pierre Fabre Sante; Pfizer Inc. </p>

<p>Peter Hajek, PhD</p>

<p>Professor of Clinical Psychology</p>

<p>Queen Mary University of London</p>

<p>London, United Kingdom</p>

<p>Disclosure: Peter Hajek, PhD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Pfizer Inc. </p>

<p>(Click here to enter...)</p>

<p>Philip Toennesen, MD, DMSc</p>

<p>Senior Consultant, Specialist in Pulmonary Medicine</p>

<p>Expert in Sleep Disorders and Smoking Cessation</p>

<p>Department of Sleep Disorders</p>

<p>Rigshospitalet</p>

<p>Copenhagen, Denmark</p>

<p>Disclosure: Philip Toennesen, MD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Fertim Pharma; Pfizer Inc.</p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: Fertim Pharma; Pfizer Inc. </p>

<p>Serena Tonstad, MD, PhD</p>

<p>Professor</p>

<p>Loma Linda University</p>

<p>Loma Linda, California, United States </p>

<p>Head Physician</p>

<p>Oslo University Hospital</p>

<p>Oslo, Norway</p>

<p>Disclosure: Serena Tonstad, MD, PhD, has disclosed the following relevant financial relationships: </p>

<p>&#9746; Served as an advisor or consultant for: Pfizer Inc. </p>

<p>&#9746; Served as a speaker or a member of a speakers bureau for: Pfizer Inc. </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Program Details</strong></p>

<p><strong>***A start and end time for the overall event are required - specific start times for each section are optional, if available. Please use 24-hour clock for international programs***</strong></p>

<p><strong>e.g.:</strong></p>

<p>October 31, 2017  </p>

<p>5:30 AM</p>

<p>Breakfast &amp; Registration</p>

<p>6:00 AM</p>

<p>Presentation</p>

<p>6:30 AM</p>

<p>Welcome and Introductions</p>

<p>Marin H. Kollef, MD</p>

<p>7:00 AM</p>

<p>Respiratory Failure and Ventilator-Associated Pneumonia: A Critical Problem For Critical Care</p>

<p>Andrew F. Shorr, MD</p>

<p>7:30 AM</p>

<p>Treating Gram-Negative Pneumonia Today: Challenges and Considerations</p>

<p>Lee E. Morrow, MD</p>

<p>8:00 AM</p>

<p>Treating Gram-Negative Pneumonia Tomorrow: Inhaled Antibiotics</p>

<p>Marin H. Kollef, MD</p>

<p>8:30 AM</p>

<p>Antimicrobial Stewardship</p>

<p>Richard G. Wunderink, MD</p>

<p>9:00 AM</p>

<p>Closing Remarks</p>

<p>Marin H. Kollef, MD</p>

<p>9:30 AM</p>

<p>Question &amp; Answer</p>
</td>
<td><p>September 7, 2018</p>

<p>12:30</p>

<p>Welcome and Introductions</p>

<p>Henri-Jean Aubin, MD, PhD</p>

<p>12:33</p>

<p>The Importance of a Complete Quit</p>

<p>Henri-Jean Aubin, MD, PhD</p>

<p>12:43</p>

<p>Pharmacologic Therapies for Smoking Cessation: The Evidence</p>

<p>Serena Tonstad, MD, PhD</p>

<p>12:53</p>

<p>E-Cigarettes and "Heat-Not-Burn" Devices: Is There a Role?</p>

<p>Peter Hajek, PhD</p>

<p>13:03</p>

<p>What Do the Guidelines Say?</p>

<p>Philip Toennesen, MD, DMSc</p>

<p>13:13</p>

<p>Panel Debate, Discussion, and Audience Q&amp;A</p>

<p>All Faculty</p>

<p>13:28</p>

<p>Wrap-Up and Closing Remarks </p>
</td>
</tr>

</table>
<h1>
<a name="_Toc512249904"></a><a name="Heading258"></a>Activity Information</h1>
<h2>
<a name="_Toc512249905"></a><a name="Heading259"></a>Left-side Content</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Target Audience</strong></p>

<p><strong>(use the applicable statement)</strong></p>
</td>
<td><p>For OUS activities: This activity is intended for an international audience of non-US psychiatrists and other healthcare professionals who are involved in the management of patients who wish to stop smoking tobacco.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Goal Statement</strong></p>
</td>
<td><p>The goal of this activity is to improve physician education regarding the role of pharmacologic and nonpharmacologic approaches when managing patients who wish to stop smoking tobacco.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Learning Objectives and KMI Map</strong></p>

<p>Learning objectives are needed for registration page, print materials, and certificate page. KMI map is for internal CME review of the enduring activity only.</p>
</td>
<td><p><strong>Upon completion of this activity, participants will:</strong></p>

<p><strong>Question type answering this objective</strong></p>

<p><strong>Question #</strong></p>

<p>Have increased knowledge regarding </p>

<p>The evidence base for pharmacologic treatment strategies for achieving a complete quit</p>

<p>Posttest</p>

<p>1</p>

<p>The evidence base for e-cigarettes and other devices with respect to a complete quit</p>

<p>Posttest</p>

<p>2</p>

<p>Have greater competence related to</p>

<p>Advising, guiding, and helping patients to achieve a complete quit</p>

<p>Posttest</p>

<p>3</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Association Disclaimer Statement (optional)</strong></p>

<p><em>(e.g., Disclaimer: The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Industry Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.)</em></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h2>
<a name="_Toc512249906"></a><a name="Heading295"></a>Right-side Content</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Credit Available</strong></p>

<p><strong>e.g.:</strong></p>

<p><strong>For Physicians</strong></p>

<p>Medscape, LLC designates this live activity for a maximum of X.X <em>AMA PRA Category 1 Credits</em>&#8482;. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Accreditation Statement</strong></p>

<p><strong>e.g.:</strong></p>

<p>Standard statement:</p>

<p><img height="34" width="150" src="OUS%20Psych%20TH-End%20261412.02%20v100.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v100.jpg" border="0" ></p>

<p><img height="95" width="150" src="OUS%20Psych%20TH-End%20261412.02%20v101.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v101.jpg" border="0" ></p>

<p>In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>
</td>
<td><p>[WebMD Global logo]</p>

<p>For Physicians</p>

<p>The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).</p>
</td>
</tr>

</table>
<h1>
<a name="_Toc512249908"></a><a name="Heading318"></a>Supporter/Partner</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Supporter information </strong><em>(e.g., "Supported by an independent educational grant from XXX")</em></p>
</td>
<td><p>Supported by an independent educational grant from [Pfizer logo]</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Supporter badge (for cert page and enduring page)</strong></p>

<p><strong>OUS programs also require a logo &#8211; see below</strong></p>
</td>
<td><p><img height="70" width="300" src="OUS%20Psych%20TH-End%20261412.02%20v102.jpg" 	alt="C:\Users\natashband\Desktop\pfizer-ieg-img-2018.gif" border="0" ></p>
</td>
</tr>

<tr valign="top">
<td><p><strong>For registration page: Supporter Logo (required for OUS only &#8211; this should be an image of the logo only, not a badge containing the "Supported by an..." language)</strong> </p>

<p><strong>For logos, check the Box directory for an existing file and include logo or link </strong>(<a href="https://webmd.app.box.com/files/0/f/3032075757/CME-Supporter-Badges-Logos-current">https://webmd.app.box.com/files/0/f/3032075757/CME-Supporter-Badges-Logos-current</a><a href="">)</a>. </p>

<p><strong>For OUS: If no logo badge is available on Box, please request the appropriate logo from the project team in vector format (.EPS, .AI, .SVG), and create an issue within WF for Edu Design to create. </strong></p>
</td>
<td><p>Supported by an independent educational grant from [Pfizer logo]</p>

<p><img height="75" width="130" src="OUS%20Psych%20TH-End%20261412.02%20v103.jpg" 	alt="C:\Users\natashband\Downloads\pfizer-logo-130x76.png" border="0" ></p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner Statement (if applicable &#8211; edit as needed)</strong></p>
</td>
<td><p>n/a</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Partner Logo (if applicable)</strong></p>
</td>
<td><p>n/a</p>
</td>
</tr>

</table>
<h1>
<a name="_Toc512249910"></a><a name="Heading335"></a>Design Information</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>What is your image recommendation?</strong></p>

<p><em>Write a brief description of a recommended image concept or theme. </em></p>
</td>
<td><p>https://www.shutterstock.com/image-photo/damaged-cigarette-pills-on-grey-table-616046861?src=nlsVKkllNkRr7D470Ywnfg-1-1  </p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Do you have images related to the concept to use as a guide? </strong></p>

<p>If <strong>yes</strong>, please provide the image resource(s) for concept direction.</p>

<p><em>(Note: due to usage requirements, some images may be unavailable for use)</em></p>

<p><strong>Resources:</strong></p>

<p><a href="http://shutterstock.com">shutterstock.com</a></p>

<p><a href="http://sciencesource.com">sciencesource.com</a></p>

<p>If <strong>no</strong>, please define desired concepts or description of the topic are acceptable.</p>

<p><em>(Ex. molecule, cell, doctor with patient, gears, rash)</em></p>

<p><strong>Town Hall Image Selection Guide:</strong></p>

<p><a href="https://webmd.box.com/v/TH-image-selection-guide">https://webmd.box.com/v/TH-image-selection-guide</a></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Are there any visual concepts or images to avoid?</strong></p>

<p><em>(Ex. cells, needles, pills)</em></p>
</td>
<td>&nbsp;</td>
</tr>

<tr valign="top">
<td><p><strong>Are there any color(s) to avoid? </strong></p>

<p><em>(Ex. supporter or medication colors)</em></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<p><a name="_Toc510101383"></a><a name="_Toc510101437"></a><a name="_Toc510106506"></a><img height="0" width="720" src="OUS%20Psych%20TH-End%20261412.02%20v104.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v104.jpg" border="0" ></p>
<h1>
<a name="_Toc512249911"></a><a name="Heading357"></a>CME info</h1>
<h2>
<a name="_Toc512249912"></a><a name="Heading358"></a>Additional Credit information</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Educational Design &#953;</strong></p>
</td>
<td><p>&#9746; Competence &#953;</p>
</td>
<td><p>&#9744; Performance &#953;</p>
</td>
<td><p>&#9744; Patient Outcomes &#953;</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Core Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Patient care and procedural skills</p>
</td>
<td><p>&#9746; Medical knowledge</p>
</td>
<td><p>&#9744; Practice-based learning and improvement </p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interpersonal &amp; communication skills</p>
</td>
<td><p>&#9744; Professionalism</p>
</td>
<td><p>&#9744; Systems-based practice</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>IPCE Competencies &#953;</strong></p>
</td>
<td><p>&#9744; Interprofessional Education (IPCE)</p>
</td>
<td><p>&#9744; Roles and Responsibilities</p>
</td>
</tr>

<tr valign="top">
<td>&nbsp;</td>
<td><p>&#9744; Interprofessional Communication</p>
</td>
<td><p>&#9744; Teamwork &#953;</p>
</td>
<td><p>&#9744; Values and Ethics</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Activity Length &#953;:</strong></p>
</td>
<td><p>42min video runtime</p>
</td>
</tr>

</table>
<p><a name="_Toc515459733"></a><a name="_Toc510101386"></a><a name="_Toc510101440"></a><a name="_Toc510106509"></a>General Information</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there a collection page?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; <strong>what type?</strong> (Select type...); <strong>provide name and URL:</strong> (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>If &#8216;Clinical Advances,&#8217; which bucket does the content go in?</strong> (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Add to other publications or pages?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes; add <strong>URL(s) and bucket name(s) &#953;</strong>: (Click here to enter...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Geotargets &#953;</strong></p>
</td>
<td><p><strong>1:</strong> Ex-US</p>
</td>
<td><p><strong>2:</strong> (Choose a geotarget...)</p>
</td>
<td><p><strong>3:</strong> (Choose a geotarget...)</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Peer review required?</strong></p>
</td>
<td><p>No</p>
</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>

</table>
<p></p>

<p><a name="_Toc515459734"></a>Product-Specific Information and Add-ons</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Is there an Outcomes study?</strong></p>
</td>
<td><p>No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a second Outcomes study?</strong></p>
</td>
<td><p>No</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there a Medscape Discuss or Discuss Lite?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Medscape Discuss</p>
</td>
<td><p>&#9744; Medscape Discuss Lite</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is there an associated HCP Perspective?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Is this program associated with a Patient Education Program or Destination Page?</strong></p>
</td>
<td><p>&#9746; No</p>
</td>
<td><p>&#9744; Yes</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Provide server path for Prescription to Learn PDF:</strong></p>
</td>
<td>&nbsp;</td>
</tr>

</table>
<h1>
<a name="_Toc512249913"></a><a name="Heading415"></a>Town Hall Statement and Posting Date</h1>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Event Statement</strong></p>
</td>
<td><p>This certificate page is associated with a Medscape Education event.</p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Posting Date</strong></p>
</td>
<td><p><strong>&lt;&lt;Date of Town Hall&gt;&gt;</strong></p>
</td>
</tr>

<tr valign="top">
<td><p><strong>Expiration Date</strong></p>
</td>
<td><p><strong>&lt;&lt;4 weeks from posting date&gt;&gt;</strong></p>
</td>
</tr>

</table>
<p><img height="0" width="720" src="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" border="0" ></p>
<h1>
<a name="_Toc512249914"></a><a name="Heading423"></a>Additional Disclosures</h1>
<p></p>
<h3>
<a name="_Toc512249915"></a><a name="Heading425"></a>SD/Editor/Writer Information and Disclosure Statements</h3>
<p>Wilma Guerra, BA, ELS Scientific Director, WebMD Global, LLC</p>

<p>Disclosure: Wilma Guerra, BA, ELS, has disclosed no relevant financial relationships.</p>
<h3>
<a name="_Toc512249916"></a><a name="Heading429"></a>Additional Planners/Reviewers Information and Disclosure Statements</h3>
<p></p>

<p>***Please delete the unneeded CME reviewer below, or add a custom entry for a different reviewer***</p>

<p><strong>Content Reviewer</strong></p>

<p>Esther Nyarko, PharmD Associate CME Clinical Director </p>

<p>Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.</p>
<h1>
<a name="_Toc512249917"></a><a name="Heading437"></a>Related links</h1>
<p><em>List 3 to 5 related links to </em><strong><em>content</em> &#953;</strong><em> on medscape.org and the titles of the activities to be added to this activity.</em></p>

<p>Can Smoking Only 1 Cigarette a Day Raise Cardiovascular Risk?</p>

<p><a href="https://www.medscape.org/viewarticle/894159">https://www.medscape.org/viewarticle/894159</a></p>

<p>Smoking Cessation Drug Linked to Cardiac Events</p>

<p><a href="https://www.medscape.org/viewarticle/893111">https://www.medscape.org/viewarticle/893111</a></p>

<p>Pathways to Quit: Options for Smoking Cessation Strategies</p>

<p><a href="https://www.medscape.org/viewarticle/890968">https://www.medscape.org/viewarticle/890968</a> </p>

<p><a name="_Toc510101393"></a><a name="_Toc510101447"></a><a name="_Toc510106516"></a><img height="0" width="720" src="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" border="0" ></p>
<h1>
<a name="_Toc512249918"></a><a name="Heading449"></a>Questions (fill in when appropriate, either before Live or Enduring CME review)</h1>
<p></p>
<h2>
<a name="_Toc512249919"></a><a name="Heading451"></a>CME Post-test questions</h2>
<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> </p>

<p><strong>Question 1:</strong> What were the findings from the EAGLES study?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	Varenicline and bupropion provided similar continuous abstinence rates (CAR) at weeks 9-12 vs nicotine replacement therapy (NRT) and placebo</p>

<p>&#8226;	CAR and neuropsychiatric adverse events were significantly higher with varenicline vs placebo and bupropion</p>

<p>&#8226;	Varenicline elicited significantly higher CAR with similar neuropsychiatric side effects vs all comparators </p>

<p>&#8226;	Bupropion yielded significantly longer CAR and more favorable neuropsychiatric side effects vs all comparators</p>

<p>Answer explanation: The EAGLES study compared bupropion, varenicline, NRT, and placebo in psychiatric and nonpsychiatric patients. Results showed that at weeks 9-12, varenicline provided significantly longer CAR vs bupropion and placebo, with similar rates of neuropsychiatric adverse events in all patients vs all comparators.</p>

<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> The World Health Organization (WHO) does not support the use of e-cigarettes, and they are thus banned in developing countries that follow WHO guidance and in developed countries. However, the United Kingdom medical and public health agencies support the use of e-cigarettes as a method to help tobacco smokers quit smoking. </p>

<p><strong>Question 2:</strong> What has been observed in the United Kingdom since 2015 regarding the impact of e-cigarettes on cigarette smoking? </p>

<p><strong>Answer choices &#953;: </strong></p>

<p>&#8226;	The availability of e-cigarettes has not changed the prevalence of smoking among people of all ages</p>

<p>&#8226;	The number of smokers in the United Kingdom has dropped, but with only a modest decrease among 18-24 year olds</p>

<p>&#8226;	The use of e-cigarettes has decreased the prevalence of smoking, especially among 18-24 year olds</p>

<p>&#8226;	Most people still prefer to smoke cigarettes vs e-cigarettes because the former delivers more nicotine</p>

<p>Answer explanation: Current data from the National Office of Statistics show that since 2015, smoking rates in the United Kingdom have steadily decreased, with the greatest decreases observed among 18-24 year olds. The United Kingdom now has the second lowest smoking prevalence in the European Union.</p>

<p><strong>Question type:</strong> CME Posttest</p>

<p><strong>Question Introduction (</strong><strong>optional &#953;):</strong> Frank is a 35-year-old patient who was been smoking cigarettes for 20 years. He states that he began smoking at age 15 and has been smoking about a pack a day for 10 years. He has developed a chronic cough and has had some trouble breathing on exertion. He would like to stop smoking completely to improve his overall heath. He comes to your office to discuss smoking cessation approaches.  </p>

<p><strong>Question 3:</strong> Which treatment approach would you advise the patient to provide his best chance of achieving a complete quit?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>&#8226;	Advise use of e-cigarettes for 1 month, then stop use to break nicotine addiction</p>

<p>&#8226;	Discuss pharmacologic options and regular counseling sessions </p>

<p>&#8226;	Recommend use of NRT with regular counseling sessions</p>

<p>&#8226;	Prescribe pharmacologic option and NRT and schedule follow-up in 3 months</p>

<p>Answer explanation: For patients who smoke, it is important to include regular counseling sessions to help them achieve a complete quit. Ideally, these sessions should be frequent and can be provided in a variety of formats. Although several options can be used to help smokers quit, the use of a pharmacologic option plus regular frequent counseling has been shown to be the most effective approach for smoking cessation.</p>
<h2>
<a name="_Toc512249920"></a><a name="Heading481"></a>Intra-activity questions (configure grid as needed)</h2>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than one answer?</p>
</td>
</tr>

</table>
<p><strong>Question 1:</strong> Do you think that cutting down on the number of cigarettes smoked (without pharmacologic or e-cigarette concomitant use) offers clinically meaningful reductions in smoking-related harm?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>A. Yes</p>

<p>B. No</p>

<p>C. Undecided/unsure</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than one answer?</p>
</td>
</tr>

</table>
<p><strong>Question 2:</strong> Do you feel that e-cigarettes or "heat-not-burn" devices are useful in helping people quit smoking completely?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>A. Yes</p>

<p>B. No</p>

<p>C. Undecided/unsure</p>


<table border="1" cellpadding="3" cellspacing="1">
<tr valign="top">
<td><p><strong>Y/N</strong></p>
</td>
<td><p><strong>Feature</strong></p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Required</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Poll Results</p>
</td>
</tr>

<tr valign="top">
<td><p>Y</p>
</td>
<td><p>Show Right/Wrong</p>
</td>
</tr>

<tr valign="top">
<td><p>N</p>
</td>
<td><p>Should users be able to select more than one answer?</p>
</td>
</tr>

</table>
<p><strong>Question 3:</strong> Do you think that the long-term benefits and risks of e-cigarettes or "heat-not-burn" devices have been established sufficiently to recommend these products to smokers who wish to quit?</p>

<p><strong>Answer choices &#953;:</strong></p>

<p>A. Yes -- first-line recommendation</p>

<p>B. Yes -- second-line recommendation</p>

<p>C. No</p>

<p>D. Undecided/unsure</p>

<p><img height="0" width="720" src="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" border="0" ></p>
<h1>
<a name="_Toc512249930"></a><a name="Heading533"></a>Abbreviations</h1>
<p>AE = adverse event</p>

<p>Af = Africa</p>

<p>AHA = American Heart Association</p>

<p>CI = confidence interval</p>

<p>COPD = chronic obstructive pulmonary disease</p>

<p>CVD = cardiovascular disease</p>

<p>EC = e-cigarettes</p>

<p>FDA = US Food and Drug Administration</p>

<p>FTND = Fagerstr&ouml;m Test for Nicotine Dependence</p>

<p>HR = hazard ratio</p>

<p>HTN = hypertension</p>

<p>Hx = history</p>

<p>LatAm = Latin America</p>

<p>MDD = major depressive disorder</p>

<p>ME = Middle East</p>

<p>MI = myocardial infarction</p>

<p>NHS = National Health Service</p>

<p>NRT = nicotine replacement therapy</p>

<p>NS = not significant</p>

<p>OTC = over the counter</p>

<p>PRN = as needed</p>

<p>RR = relative risk</p>

<p>Rx = prescription</p>

<p>SRNT = Society for Research on Nicotine and Tobacco</p>

<p>SR = sustained release</p>

<p>TQD = target quit date</p>

<p>WHO = World Health Organization</p>

<p><a name="_Toc510101462"></a><a name="_Toc510106530"></a><img height="0" width="720" src="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" border="0" ></p>
<h1>
<a name="_Toc512249931"></a><a name="Heading562"></a>Transcript, chapter titles, and time codes (for enduring version only)</h1>
<p></p>

<p><strong>&lt;&lt;level 1&gt;&gt; Program Introduction</strong></p>

<p><strong>&lt;&lt;insert Slide 1; Chapter title: Program Introduction; 00:00&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;</strong> <strong>The Big Debate: Pharmacologic vs Alternative Approaches in Smoking Cessation</strong></p>

<p><strong>&lt;&lt;insert Slide 2; 00:10&gt;&gt;</strong> </p>

<p><strong>&lt;&lt;level 2&gt;&gt; Program Agenda</strong></p>

<p>&lt;&lt;Intra-activity question 1; 00:46&gt;&gt;  </p>

<p>&lt;&lt;Intra-activity question 2; 00:51&gt;&gt;  </p>

<p>&lt;&lt;Intra-activity question 3; 00:52&gt;&gt;  </p>

<p><strong>&lt;&lt;level 1&gt;&gt; The Importance of a Complete Quit </strong></p>

<p><strong>&lt;&lt;insert slide 3; Chapter title: The Importance of a Complete Quit; 00:53&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; The Importance of a Complete Quit</strong></p>

<p><strong>&lt;&lt;insert slide 4; Chapter title: Morbidity and Mortality Related to Smoking; 01:00&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Worldwide Leading Causes of Attributable Global Mortality<sup>[1]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 5; 01:19&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Smoking Leads to an 11-Year Loss of Life Span<sup>[2]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 6; 01:37&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Mortality and Morbidity Rates Associated With Smoking<sup>[2,3]</sup></strong></p>

<p>&#8226;	The figure on the left shows that there is a monotonous dose effect relationship between cigarettes per day and all-cause mortality</p>

<p><tt>o	</tt>This means that even low smoking rates are associated with an increased risk of mortality </p>

<p>&#8226;	In the specific case of cardiovascular disease, most of the mortality risk is borne by low smoking rates, as seen in the curve on the right </p>

<p><strong>&lt;&lt;insert Slide 7; 02:17&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Mortality and Morbidity Rates Associated With Smoking (cont)<sup>[2,4]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 8; Chapter title: Mortality Risk Reduction After Smoking Cessation or Reduction; 02:46&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; All-Cause Mortality Risk Reduction After Quitting Smoking<sup>[5]</sup></strong></p>

<p>&#8226;	It is believed that complete quit is the safest and most effective way to reduce the all-cause mortality associated with smoking</p>

<p>&#8226;	It is also believed that the reduction of all-cause mortality stabilizes roughly 10 to 15 years after complete smoking cessation</p>

<p><strong>&lt;&lt;insert Slide 9; 03:15&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Little Evidence of All-Cause Mortality Risk Reduction After Smoking Reduction<sup>[6-9]</sup></strong></p>

<p>&#8226;	It is important to keep in mind that in all the studies shown on this slide, smoking reduction was not supported by any nicotine replacement use </p>

<p>&#8226;	Moreover, it is known that reduction of cigarettes per day does not reflect reduction of toxin exposure</p>

<p><strong>&lt;&lt;insert Slide 1; 04:21&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Harm Reduction Concept: People Who Do Not Want to Give Up Tobacco or Nicotine Use Completely<sup>[10]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 11; 05:18&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Cigarette Smoking Causes the Most Harm<sup>[11]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 12; Chapter title: Conclusions; 06:42&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Conclusions</strong></p>

<p><strong>&lt;&lt;level 1&gt;&gt; Pharmacologic Therapies for Smoking Cessation: The Evidence</strong></p>

<p><strong>&lt;&lt;insert Slide 13; Chapter title: Pharmacologic Therapies; 07:20&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Pharmacologic Therapies for Smoking Cessation: The Evidence</strong></p>

<p><strong>&lt;&lt;insert Slide 14; Chapter title: First-Line Drugs; 07:50&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Nicotine Replacement Therapy vs Control for Smoking Cessation<sup>[12]</sup></strong></p>

<p>&#8226;	Nicotine replacement therapy is the oldest, most established, and most used therapy for smoking cessation</p>

<p>&#8226;	Based on the results of this analysis, the Cochrane Group collaborators stated that they will never do another meta-analysis of this type, because the evidence is so strong for nicotine replacement against placebo</p>

<p><tt>o	</tt>Subgroup and other types of analyses may be conducted, for example, comparing nicotine replacement with e-cigarettes or other comparators, but the placebo comparison is firmly established at this time</p>

<p><strong>&lt;&lt;insert Slide 15; 09:57&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; First-Line Drugs in Smoking Cessation: Meta-Analysis of Cochrane Register Efficacy Data<sup>[12-15]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 16; Chapter title: Varenicline; 11:44&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Efficacy of Varenicline: Phase 3 and 4 Studies (Weeks 9-12)<sup>[16-25]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 17; 12:48&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Efficacy of Varenicline: Phase 3 and 4 Studies (Weeks 9-52)<sup>[16,17,21-23,25]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 18; 13:11&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Quit Rates Flexible Quit Date Study<sup>[24]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 19; Chapter title: Maintenance Therapy With Varenicline; 13:34&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Varenicline Maintenance Study<sup>[26]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 20; 14:23&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Maintenance Treatment With Varenicline in Patients With Schizophrenia and Bipolar Disorder<sup>[27]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 21; Chapter title: EAGLES Study; 14:48&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; EAGLES: Continuous Abstinence Rates in Psychiatric and Nonpsychiatric Cohorts<sup>[28]</sup></strong></p>

<p>&#8226;	This is the EAGLES study and included over 8000 subjects, both people with psychiatric disease and people without known psychiatric disease</p>

<p>&#8226;	The study was sponsored by both producers of varenicline and of bupropion and in collaboration with health authorities</p>

<p><strong>&lt;&lt;insert Slide 22; 15:52&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Primary Endpoint for the EAGLES Study: Nonpsychiatric Adverse Events<sup>[28]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 23; Chapter title: Tolerability and Safety of Available Therapies; 16:57&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Tolerability and Safety Issues<sup>[29]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 24; Chapter title: Physician vs Patient Perspectives; 17:12&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Physician Perspectives<sup>[30]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 25; 19:20&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;Lack of Readiness to Use Pharmacologic Options (Smoker)</strong></p>

<p><strong>&lt;&lt;level 1&gt;&gt; E-Cigarettes and "Heat-Not-Burn" Devices</strong> <strong>&lt;&lt;insert Slide 26 Chapter title: E-Cigarettes and "Heat-Not-Burn" Devices; 20:19&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; E-Cigarettes and "Heat-Not-Burn" Devices: Is There a Role?</strong></p>

<p><strong>&lt;&lt;insert Slide 27; Chapter title: The Current Controversy; 20:30&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Current Controversy</strong></p>

<p>&#8226;	In my opinion, what we see in our field is this split in the attitude to e-cigarettes, which I believe is based on priority</p>

<p>&#8226;	If the priority is smoke-related death and disease, then there is a sort of pragmatic perspective in which alternative lower-risk nicotine devices may appear as promising to lower the total of death and disease from smoking</p>

<p>&#8226;	By contrast, the other view is the concern that providing nicotine in the less dangerous form still maintains and may even increase nicotine use in the population</p>

<p><tt>o	</tt>Hence, safe nicotine devices are both a problem and a risk</p>

<p><strong>&lt;&lt;insert Slide 28; Chapter title: The UK Perspective on E-Cigarettes; 22:07&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Recent UK Reports Regarding the Use of E-Cigarettes<sup>[31-33]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 29; 22:19&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Conclusions of UK Reviews</strong></p>

<p><strong>&lt;&lt;insert Slide 30; 23:20&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; The Opposite View</strong></p>

<p><strong>&lt;&lt;insert Slide 31; 23:36&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Time Will Tell</strong></p>

<p><strong>&lt;&lt;insert Slide 32; 24:04&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; UK Experience So Far</strong></p>

<p><strong>&lt;&lt;insert Slide 33; 25:00&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; "Heat-Not-Burn" Products<sup>[34]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 34; 25:45&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Cigarette Sales Decline: Japan, 2014-2018</strong></p>

<p><strong>&lt;&lt;insert Slide 35; Chapter title: The DUO Study; 26:00&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt;The DUO Study<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 36; 26:11&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Background<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 37; 26:36&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; DUO Study<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 38; 26:50&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Study Procedures<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 39; 27:32&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Are Dual Users Interested in Varenicline?<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 40; 27:51&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Did Those Wanting and Not Wanting Varenicline Differ?<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 41; 28:31&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Quitting Outcomes<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 42; 28:44&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Quitting Vaping, Smoking, and Both<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 43; 29:07&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Changes in Enjoyment of Smoking and Vaping<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 44; 29:31&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Conclusions<sup>[35]</sup></strong></p>

<p><strong>&lt;&lt;level 1&gt;&gt; Current Guidelines</strong></p>

<p><strong>&lt;&lt;insert Slide 45; Chapter title: Current Guidelines; 30:00&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; What Do the Guidelines Say?</strong></p>

<p><strong>&lt;&lt;insert Slide 46; Chapter title: WHO Recommendations; 30:10&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; WHO Framework Convention on Tobacco Control<sup>[36]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 47; 30:55&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; WHO Urges Restrictions on E-Cigarettes (2016)<sup>[37]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 48; 31:10&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Interventions to Reduce Harm From Continued Tobacco Use<sup>[10]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 49; Chapter title: NICE Guideline; 32:57&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; NICE 2018: 1.5 Advice on E-Cigarettes for Health and Social Care Workers in Primary and Community Settings<sup>[38]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 50; Chapter title: Analysis of National Guidelines; 33:26&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Clinical Guidelines for General Practice<sup>[39]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 51; 34:04&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Clinical Guidelines for General Practice (cont)<sup>[39]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 52; 35:42&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Clinical Guidelines for General Practice (cont)<sup>[39]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 53; Chapter title: Canadian Guidelines; 36:25&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Canadian Smoking Cessation Guideline Summary Statement<sup>[40]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 54; 36:32&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Canadian Smoking Cessation Guideline Summary Statement (cont)<sup>[40]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 55; 36:40&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Canadian Smoking Cessation Guideline Summary Statement (cont)<sup>[40]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 56; Chapter title: Medical Societies; 37:03&gt;&gt;</strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Medical Societies</strong></p>

<p><strong>&lt;&lt;insert Slide 57; 37:55&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; AHA Smoking Guidelines 2014</strong></p>

<p><strong>&lt;&lt;insert Slide 58; 38:46&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Position Statement of the Forum of International Respiratory Societies: E-Cigarettes<sup>[41]</sup></strong></p>

<p><strong>&lt;&lt;insert Slide 59; 39:42&gt;&gt; </strong> <strong>&lt;&lt;level 2&gt;&gt; Conclusions</strong></p>

<p>&lt;&lt;Intra-activity question 1; 42:00&gt;&gt;  </p>

<p>&lt;&lt;Intra-activity question 2; 42:02&gt;&gt;  </p>

<p>&lt;&lt;Intra-activity question 3; 42:05&gt;&gt;  </p>

<p><strong>&lt;&lt;insert Slide 60; 42:08&gt;&gt; </strong></p>

<p><strong>&lt;&lt;level 2&gt;&gt; Thank You</strong></p>

<p><em>This content has been condensed for improved clarity.</em></p>

<p><strong>&lt;&lt;end slides&gt;&gt;</strong></p>

<p><img height="0" width="720" src="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" 	alt="OUS%20Psych%20TH-End%20261412.02%20v105.jpg" border="0" ></p>
<h1>
<a name="_Toc512249932"></a><a name="Heading775"></a>References (for enduring version only)</h1>
<p>1.	Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <em>Lancet. </em>2012;380:2224-2260.</p>

<p>2.	Pirie K, Peto R, Reeves GK, et al. The 21st century hazard of smoking and benefits of stopping: a prospective study of one million women in the UK. <em>Lancet. </em>2013;381:133-141.</p>

<p>3.	Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. <em>J Am Coll Cardiol</em>. 2015;66:1378-1391.</p>

<p>4.	Hackshaw A, Morris JK, Boniface S, et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. <em>BMJ</em>. 2018;360:j5855.</p>

<p>5.	Hu Y, Zong G, Liu G, et al. Smoking cessation, weight change, type 2 diabetes, and mortality. <em>N Engl J Med. </em>2018;379:623-632. </p>

<p>6.	Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19.372 men and women from The Copenhagen Centre for Prospective Population Studies. <em>Am J Epidemiol. </em>2002;156:994-1001. </p>

<p>7.	Tverdal A, Bjartveit K. Health consequences of reduced dailt cigarette consumption. <em>Tobacco Control. </em>2006;15:472-480.</p>

<p>8.	Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and lifetime mortality risk in men: a prospective cohort study. <em>Am J Epidemiol. </em>2012;175:1006-1012. </p>

<p>9.	Hart C, Gruer L, Bauld L. Does smoking reduction in midlife reduce mortality risk? Results of 2 long-term prospective cohort studies of men and women in Scotland. <em>Am J Epidemiol. </em>2013;178:770-779.</p>

<p>10.	Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, et al. Interventions to reduce harm from continued tobacco use. <em>Cochrane Database Syst Rev. </em>2016;10:Cd005231. </p>

<p>11.	Abrams DB, Glasser AM, Pearson JL, et al. Harm minimization and tobacco control: reframing societal views of nicotine use to rapidly save lives. <em>Annu Rev Public Health. </em>2018;39:193-213. </p>

<p>12.	Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation (review). <em>Cochrane Database Sys Rev. </em>2018;5:CD000146.</p>

<p>13.	Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. <em>Cochrane Database Syst Rev. </em>2013;4:CD006103. </p>

<p>14.	Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. <em>Cochrane Database Syst Rev. </em>2012;4. </p>

<p>15.	Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. <em>Cochrane Database Syst Rev. </em>2016;5:CD006103</p>

<p>16.	Gonzales D, Rennard SI, Nides M, et al; for the Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. <em>JAMA</em>. 2006;296:47-55. </p>

<p>17.	Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. <em>JAMA</em>. 2006;296:56-63. </p>

<p>18.	Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. <em>Clin Ther.</em> 2007;29:1027-1039. </p>

<p>19.	Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. <em>Respirology</em> 2009;14:384-392. </p>

<p>20.	Bolliger CT, Issa JS, Posadas-Valay R, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. <em>Clin Ther. </em>2011;33:465-477. </p>

<p>21.	Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. <em>Circulation. </em>2010; 121:221-229.</p>

<p>22.	Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. <em>Chest.</em> 2011;139:591-599. </p>

<p>23.	Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. <em>Ann Int Med</em> 2013;159:390-400. </p>

<p>24.	Rennard S, Hughes J, Cinciripini PM, et al; Flexible Quit Date Study Group. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. <em>Nic Tob Research</em> 2012;14:343-350.</p>

<p>25.	Gonzales D, Hajek P, Pliamm L, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. <em>Clin Pharm Therap.</em> 2014;96:390-396.</p>

<p>26.	Tonstad S, T&oslash;nnesen P, Hajek P, et al; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. <em>JAMA. </em>2006;296:64-71. </p>

<p>27.	Evins E, Cather C, Pratt SA. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized, clinical trial. <em>JAMA. </em>2014;311:145-154.</p>

<p>28.	Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <em>Lancet. </em>2016;387:2507-2520.</p>

<p>29.	Barboza JL, Patel R, Patel P, et al. An update on the pharmacotherapeutic interventions for smoking cessation. <em>Expert Opin Pharmacother. </em>2016;17:1483-1496.</p>

<p>30.	Bartsch AL, H&auml;rter M, Niedrich J, et al. A systematic literature review of self-reported smoking cessation counseling by primary care physicians. <em>PLoS One. </em>2016;11:e0168482.</p>

<p>31.	Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction. April 2016. <a href="https://www.rcplondon.ac.uk/file/3563/download?token=Mu0K_ZR0">https://www.rcplondon.ac.uk/file/3563/download?token=Mu0K_ZR0</a>. Accessed October 12, 2018.</p>

<p>32.	McNeill A, Brose LS, Calder R, et al. E-cigarettes: an evidence update. A report commissioned by Public Health England. 2015. <a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/733022/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/733022/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf</a>. Accessed October 12, 2018.</p>

<p>33.	McNeill A, Brose LS, Calder R, et al. Evidence review of e-cigarettes and heated tobacco products 2018. A report commissioned by Public Health England. 2018. <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products_2018.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products_2018.pdf</a>. Accessed October 12, 2018.</p>

<p>34.	Japan Tobacco Inc. Japanese Domestic Cigarette Sales Results for July 2018. August 17, 2018. <a href="https://www.jt.com/media/news/2018/pdf/20180817_02.pdf">https://www.jt.com/media/news/2018/pdf/20180817_02.pdf</a>. Accessed October 12, 2018. </p>

<p>35.	Hajek P, Peerbux S, Philips-Waller A, et al. Interest in using varenicline and its effects in people who both smoke and vape. Poster presented at: Society for Research on Nicotine and Tobacco Europe 18<sup>th</sup> Annual Conference; September 6-8, 2018; Munich, Germany. Med-1.</p>

<p>36.	World Health Organization. <em>WHO Framework Convention on Tobacco Control.</em> Geneva, Switzerland; World Health Organization; 2003.</p>

<p>37.	Gulland A, et al. WHO urges restrictions on e-cigarettes. <em>BMJ </em>2016;355:i5991.</p>

<p>38.	National Institute for Health Care Excellence. Stop smoking interventions and services. NICE guideline NG92. March 28, 2018. nice.org.uk/guidance/ng92. Accessed October 12, 2018.</p>

<p>39.	Verbiest M, Brakema E, van der Kleij R, et al. National guidelines for smoking cessation in primary care: a literature review and evidence analysis. <em>NPJ Prim Care Respir Med. </em>2017;27:2</p>

<p>40.	Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-informed Tobacco Treatment (CAN-ADAPTT). Canadian Smoking Cessation Clinical Practice Guideline. 2011. <a href="https://www.peelregion.ca/health/professionals/events/pdf/2013/canadaptt-summary-statements.pdf">https://www.peelregion.ca/health/professionals/events/pdf/2013/canadaptt-summary-statements.pdf</a>. Accessed October 12, 2018. </p>

<p>41.	Schraufnagel DE, Blasi F, Drummond MB, et al; Forum of International Respiratory Societies. Electronic cigarettes. A position statement of the forum of international respiratory societies. <em>Am J Respir Crit Care Med. </em>2014;190:611-618. </p>


</body>

</html>
